Adults suffering from hemophilia in Poland are struggling to access treatment with emicizumab, a modern therapy that significantly improves their quality of life but is not reimbursed for adults without inhibitors.
Hemophilia has long dictated the lives of those affected, with constant infusions, fear of movement, pain, and gradual loss of mobility being common experiences. Modern hematology has made great strides, offering therapies that allow patients to live nearly normal lives, yet access in Poland remains limited. Emicizumab, a breakthrough treatment for hemophilia A recognized globally, is currently not reimbursed for adult patients without inhibitors, the largest group of those suffering from this condition.
Hemophilia A and B are X-linked inherited disorders caused by mutations in the genes coding for coagulation factors VIII and IX, respectively. This results in impaired blood clotting, meaning even minor injuries can lead to prolonged bleeding, while those with the severe form of the disease may experience spontaneous bleeding without any clear cause. Common complications include joint bleeding, which can lead to lasting damage and disability, especially when not effectively managed.
The lack of reimbursement for emicizumab has significant implications for adults with hemophilia, who may continue to face debilitating symptoms and a higher risk of complications. The situation highlights an urgent need for policy change to ensure equitable access to life-altering treatment, as current restrictions disproportionately affect the most vulnerable patients, denying them the chance to lead more normal lives online medical services and treatment innovations.
